Repurposing antifungal drugs for cancer therapy,Journal of Advanced Research

当前位置： X-MOL 学术 › J. Adv. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Repurposing antifungal drugs for cancer therapy
Journal of Advanced Research ( IF 11.4 ) Pub Date : 2022-09-05 , DOI: 10.1016/j.jare.2022.08.018
Ningna Weng ₁ , Zhe Zhang ₂ , Yunhan Tan ₃ , Xiaoyue Zhang ₄ , Xiawei Wei ₅ , Qing Zhu ₆

Affiliation

Background

Repurposing antifungal drugs in cancer therapy has attracted unprecedented attention in both preclinical and clinical research due to specific advantages, such as safety, high-cost effectiveness and time savings compared with cancer drug discovery. The surprising and encouraging efficacy of antifungal drugs in cancer therapy, mechanistically, is attributed to the overlapping targets or molecular pathways between fungal and cancer pathogenesis. Advancements in omics, informatics and analytical technology have led to the discovery of increasing “off-site“ targets from antifungal drugs involved in cancerogenesis, such as smoothened (D477G) inhibition from itraconazole in basal cell carcinoma.

Aim of review

This review illustrates several antifungal drugs repurposed for cancer therapy and reveals the underlying mechanism based on their original target and “off-site” target. Furthermore, the challenges and perspectives for the future development and clinical applications of antifungal drugs for cancer therapy are also discussed, providing a refresh understanding of drug repurposing.

Key scientific concepts of review

This review may provide a basic understanding of repurposed antifungal drugs for clinical cancer management, thereby helping antifungal drugs broaden new indications and promote clinical translation.

中文翻译：

将抗真菌药物重新用于癌症治疗

背景

与癌症药物发现相比，抗真菌药物在癌症治疗中的重新利用由于具有安全性、高成本效益和节省时间等特定优势，在临床前和临床研究中引起了前所未有的关注。从机制上讲，抗真菌药物在癌症治疗中令人惊讶和令人鼓舞的功效归因于真菌和癌症发病机制之间的重叠靶点或分子途径。组学、信息学和分析技术的进步导致人们发现了越来越多与癌发生相关的抗真菌药物的“异位”靶标，例如伊曲康唑对基底细胞癌的平滑抑制 (D477G)。